Robin Hood Ventures

We've raised $50M to advance AI-driven pathology and deliver the future of precision medicine! ?? Read the release for details: https://bit.ly/4bFiY8L Pathology is the bedrock of up to 70% of clinical decisions and every new drug brought to market—yet it remains one of the last fields in medicine to fully modernize despite rising case volume and a shrinking workforce. We believe that pathologists, scientists, and the patients they serve deserve more. With this funding, we will advance our mission to rewire pathology by growing our footprint and advancing Concentriq, with a focus on weaving AI into its core. This will enable us to: ?? Speed up the development of novel therapies ? Accelerate diagnosis ?? Match more patients with the best course of treatment Thank you to Insight Partners, Alpha Intelligence Capital, and Triangle Peak Partners for leading the round, to our other investors Avenue Capital Group, Emerald Development Managers LP, Green Park & Golf Ventures, Fusion Fund, Interwoven Ventures, and Razor's Edge Ventures, and to our customers, partners, and the #digitalpathology community for joining us on our journey. “Insight has had a long-standing thesis on digitization and AI in pathology, and we've been waiting for a winner to emerge,” said Scott Barclay, Managing Director at Insight Partners. “Proscia is poised to be that leader. With its fast-growing customer base and strong champions of its product, it will continue to solidify its position as digital pathology moves into the mainstream.”

?? BREAKING NEWS: Quartile was named to G2’s elite 2025 Best Software list for Best Commerce Products as the #1 Retail Media Advertising Platform. ?? Only 1% of G2 vendors make it onto the Best Software Awards list – and it’s all thanks to glowing reviews from our customers.???? Heartfelt thanks to the pillars of our success – our customers, partners, and team. ?? Learn more about the significance of our inclusion on?#BestSoftware2025: https://lnkd.in/eqMWkKGr?

Sauvie Inc. is continuing to advance its mission of transforming patient outcomes with next generation therapies by the collaboration with ACCELERATED BIOSCIENCES CORP. to research iPSC derived effector cells from human trophoblast stem cells (hTSC). Sauvie Inc. recognizes the synergistic potential of using hTSC, the earliest ethically sourced stem cell, to derive iPSCs and Sauvie Inc.'s CAM-V? next generation antibody program. #collaboration #savinglives #immunotherapy #generationtherapy Accelerated Biosciences and Sauvie Collaborate to Research iPSC Derived Effector Cells from Human Trophoblast Stem Cells Accelerated Biosciences and Sauvie are thrilled to announce their strategic partnership aimed at collaborating to derive human induced pluripotent stem cells (“iPSC”) derived effector cells from human trophoblast stem cells (“hTSC”).?By utilizing Accelerated Bio’s innovative hTSC platform, this partnership aims to offer iPSC derived effector cells from the earliest starting material that would provide the best iPSC platform for developing immunotherapies.?This collaboration marks Sauvie’ entry into the cell therapy area, broadening its immunotherapy modalities leveraging Accelerated Biosciences cutting-edge hTSC technology. Unparalleled hTSC platform: ·????????Cutting-Edge hTSC Platform: Accelerated Bio's hTSC platform is central to this collaboration.?Known for its high plasticity and genetic stability, hTSCs are the ideal starting material for iPSC-based therapeutic development and regenerative medicine. ? ·????????Ethically Sourced Stem Cells: The hTSCs is the earliest-stage, pre-implantation, pluripotent stem cells that are ethically sourced.?iPSC reprogrammed from hTSC would offer better characteristics than those from adult somatic cells. Through this collaboration, Sauvie and Accelerated Bio aim to establish capabilities to develop hTSC-derived iPSC compliant with FDA and EU regulatory requirements and develop new treatment options to patients. ? About Accelerated Biosciences Accelerated Bio is at the forefront of healthcare innovation, leveraging the groundbreaking potential of hTSCs to revolutionize precision medicine. Originating from an early and ethical source, hTSCs possess extraordinary abilities to perform the functions of various cell types with added genetic stability, natural immune privilege, and high expansion capacity. Accelerated Bio's extensive, robust, and unencumbered intellectual property portfolio ensures the freedom to innovate for both Accelerated Bio and its partners. For more information, please visit www.acceleratedbio.com.

Thanks to Philadelphia Alliance for Capital and Technologies (PACT) for naming Proscia as a 2025 Enterprise Awards Finalist! ?? It’s clear that Philadelphia’s innovation ecosystem is stronger than ever, and we’re honored to be part of such an inspiring community.

From Philadelphia to impact.51: Igniting a Global Movement for Women’s Health ?? What happened in Philadelphia wasn’t just an event—it was the spark of a new collaboration. A powerful partnership between impact.51 and leaders from #Philadelphia’s vibrant innovation #ecosystem, united by a shared mission: to advance #women’shealth, close critical gaps, and drive global impact. This is more than a conversation—it’s the beginning of a #movement. Together, we’re building a bridge between ecosystems, from Israel to the U.S., to push women’s health to the forefront of innovation. Karina Sotnik – Co-founder of WorldUpstart Impacts presented the collaboration between impact.51 and WorldUpstart, aimed at driving women’s health innovation forward. Michal Lebenthal Andreson, LlB introduced how impact.51 is building ventures that don’t just identify problems—they create solutions, while Michal Shalem joined an inspiring panel, challenging the status quo and emphasizing that women’s health is not a niche market but a global priority. A special thank you to Maiken Scott, of WHYY's The Pulse, whose thoughtful moderation elevated the discussion, to Fred Walker, who shared in the panel valuable insights from the Hologic, Inc. Global Women’s Health Index, and to the brilliant panelists—Heather A. Steinman, PhD, MBA, Linara Axanova, and M Alexandra Monroy PhD, —all #changemakers in their fields. Key takeaways from the discussion: ?? We can’t fix what we don’t understand. The lack of comprehensive data on women’s health affects everything from diagnosis to treatment. ?? Bias isn’t invisible—it’s measurable. Only 4% of healthcare R&D funding goes to women’s health. This isn’t just a gap; it’s an untapped opportunity for transformative #innovation. ?? Innovation isn’t just about new tech—it’s about new priorities. To truly advance, we must fund women’s health ventures at scale and ensure solutions reach the women who need them most. ?? We’re not here to highlight gaps—we’re here to close them. ?? We’re not here to talk about change—we’re here to lead it. ?? Innovation is our tool, systemic change is our goal A heartfelt thank you to WorldUpstart, Stephanie Vogel, for her outstanding leadership in organizing and bringing this event to life, Robin Hood Ventures, and BioLabs #Philadelphia for creating the space for this dialogue—and more importantly, for action. This is just the beginning. We're building the future of women’s health—together! ?? Photos: KP Photography #FemTech #womenHealthcareRevolution #womenhealthmatters #HealthcareInnovation #PhillyTech Michal Elovitz, MD Mitzi Krockover, MD Marissa Fayer Leslie C. Cohen Kimberly Wexler Klayman Levi Shapiro ??Heidi Diamond Nicky Newfield Beth Cohen Louise Yochee Klein

? That’s a wrap for the final leg of Startup Nation Central's Health Tech Roadshow culminating in our favorite city: Philadelphia. Amid the Super Bowl buzz, eight innovative startups developing solutions to some of healthcare’s most pressing challenges were introduced to key leaders across our ecosystem, all aimed at helping them navigate the U.S. healthcare market. ?? This wasn’t just an "innovation showcase." The founders had the opportunity to engage in one-on-one meetings with industry-leading investors, executives from major health systems, and other strategic connections—all designed to provide actionable guidance as they work to scale in the U.S. Congratulations to the founders for completing the program—we can't wait to see you back in Philadelphia soon! ?? aryeh katz, 6Degrees LTD ?? Justin Kiessling and Frank Trigg, MBA, Briya ?? Vered Bar and Ronen Viner, CURESPONSE ?? Tal Shapsa Heiman and Inbal Mayan MD, Epilog ?? Ilay Marom, NaNose Medical ?? Rich Vogel, Nervio ?? Talia Cohen Solal, NeuroKaire (formerly Genetika+) ?? Raz Evenor, Predicta Med A big thank you to the investors, mentors, and thought leaders who shared their valuable time and expertise: Gaingels Neuvation Ventures Empactful Capital Robin Hood Ventures Jefferson Health Royer Cooper Cohen Braunfeld LLC (RCCB) Laguna Health Penn Medicine, University of Pennsylvania Health System BIRD Foundation Morgan, Lewis & Bockius LLP American Board of Internal Medicine ChristianaCare Cerity Partners CIC (Cambridge Innovation Center) The Chamber of Commerce for Greater Philadelphia Philadelphia Department of Commerce Philadelphia-Israel Chamber of Commerce OVA Solutions Research Lifecycle Solutions And last but certainly not least, thank you to our partners at Startup Nation Central and 8400 The Health Network who made it all possible.

We're #hiring! Apply today or share this post with your network.